GSK innovation fund scouts Canadian biotechs; Arena raising cash; Gamida Cell raises $10M;

 @FierceBiotech: MIT: Staggering cancer drugs can make them more effective. More | Follow @FierceBiotech

 @RyanMFierce: It's only a matter of time before fat taxes are everywhere. Obesity costs too much, and taxes on smokes paved the way. Report | Follow @RyanMFierce

 @JohnCFierce: Stealth no more: Ra Pharma in Cambridge nails $8.6M venture tranche, targets hereditary angioedema for the lead. Article | Follow @JohnCFierce

> GSK ($GSK) execs are talking up their $50 million "innovation" fund, which is bankrolling early-stage biotechs in the Quebec area. Story

> With its prospects for lorcaserin looking good these days, Arena Pharmaceuticals ($ARNA) says it will raise some extra cash through the sale of common stock. Report

> Gamida Cell has raised $10 million to back the launch of its lead cell therapy product. Report

> Pfizer ($PFE) says Torisel flunked a Phase III comparison study with Nexavar for renal cell carcinoma. Release

Pharma News

 @FiercePharma: Patients 'waiting up to nine years' for NICE to approve drugs, a U.K. study finds--TelegraphStory | Follow @FiercePharma

> Top 10 Best-selling Cancer Drugs in 2011. Special Report

> New discount persuades NICE to bless J&J's Zytiga. News

> U.K. report says NICE drags its feet on drug approvals. Article

Medical Device News

 @FierceMedDev: Folks, the clock is ticking. Get your nominations in for the 15 fiercest device developers. Survey | Follow @FierceMedDev

> NeuroSigma buys patents that advance TFN stents. Report

> OraSure's OTC HIV test wins crucial FDA panel backing. Article

> Medtronic's Resolute Integrity stent gains CE mark for 7 new indications. More

> St. Jude wins CE mark for hypertension treatment device. Item

Drug Delivery News

 @DamianFierce: Using self-assembling DNA tubes, Harvard researchers plan to effectively deliver drugs to cells. News | Follow @DamianFierce

> UNC researchers craft siRNA platform that can switch its solubility. Report

> MIT: Staggering cancer drugs can make them more effective. Story

> Japanese firm buys Altea's assets, plans to launch transdermal tech. Article

> D. Medical signs worldwide marketing deal for insulin-delivery tech. Item

Biomarkers News

> Genes tag schizophrenia risk. More

> Proteins in a drop of fluid mark osteoarthritis risk. Report

> Early pancreatic biomarker could spot killer disease. Article

> Gene IDs fast-onset Parkinson's disease. Story

And Finally… Investigators say they successfully slowed down the biological clock in mice in a proof of principle study that spurred expression of telomerase. Release


Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.